CY1114307T1 - Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν - Google Patents

Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν

Info

Publication number
CY1114307T1
CY1114307T1 CY20131100486T CY131100486T CY1114307T1 CY 1114307 T1 CY1114307 T1 CY 1114307T1 CY 20131100486 T CY20131100486 T CY 20131100486T CY 131100486 T CY131100486 T CY 131100486T CY 1114307 T1 CY1114307 T1 CY 1114307T1
Authority
CY
Cyprus
Prior art keywords
aquorin
compositions containing
methods used
methods
preventing
Prior art date
Application number
CY20131100486T
Other languages
Greek (el)
English (en)
Inventor
Mark Y Underwood
Original Assignee
Quincy Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience, Llc filed Critical Quincy Bioscience, Llc
Publication of CY1114307T1 publication Critical patent/CY1114307T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
CY20131100486T 2004-06-21 2013-06-14 Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν CY1114307T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
EP05766584.6A EP1768691B1 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (1)

Publication Number Publication Date
CY1114307T1 true CY1114307T1 (el) 2016-08-31

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100486T CY1114307T1 (el) 2004-06-21 2013-06-14 Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν

Country Status (20)

Country Link
US (3) US20060229243A1 (enExample)
EP (2) EP1768691B1 (enExample)
JP (1) JP4971150B2 (enExample)
KR (1) KR101213555B1 (enExample)
CN (1) CN1997383B (enExample)
AU (1) AU2005265266B2 (enExample)
BR (1) BRPI0512392B1 (enExample)
CA (1) CA2571542C (enExample)
CY (1) CY1114307T1 (enExample)
DK (1) DK1768691T3 (enExample)
ES (1) ES2422173T3 (enExample)
IL (1) IL180195A (enExample)
MX (1) MXPA06015037A (enExample)
NZ (1) NZ552274A (enExample)
PL (1) PL1768691T3 (enExample)
PT (1) PT1768691E (enExample)
SG (1) SG153848A1 (enExample)
SI (1) SI1768691T1 (enExample)
WO (1) WO2006010004A2 (enExample)
ZA (1) ZA200610688B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) * 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
MX2010009753A (es) * 2008-03-11 2010-09-30 Quincy Bioscience Llc Composiciones que contienen apoaecuorina y metodos de uso de las mismas.
JP2010143860A (ja) * 2008-12-19 2010-07-01 Chisso Corp タンパク質の安定化剤
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
WO2012086756A1 (ja) * 2010-12-24 2012-06-28 大塚製薬株式会社 生理活性物質を検出するバイオアッセイ法
SG11201402364WA (en) * 2011-11-15 2014-09-26 Quincy Bioscience Llc Apoaequorin for reducing neuronal injury due to ischemia
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device
USD1042180S1 (en) 2020-05-28 2024-09-17 Calcivis Limited Dental detection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
US6930169B2 (en) * 2000-06-12 2005-08-16 University Of Baltimore Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Also Published As

Publication number Publication date
CN1997383A (zh) 2007-07-11
EP1768691A4 (en) 2010-08-04
CA2571542A1 (en) 2006-01-26
US20100152117A1 (en) 2010-06-17
KR101213555B1 (ko) 2012-12-18
KR20070070154A (ko) 2007-07-03
BRPI0512392A (pt) 2008-03-11
EP1768691B1 (en) 2013-05-22
HK1109576A1 (en) 2008-06-13
EP2545934A1 (en) 2013-01-16
US20080287350A1 (en) 2008-11-20
MXPA06015037A (es) 2007-07-11
AU2005265266B2 (en) 2011-05-12
ZA200610688B (en) 2007-12-27
SI1768691T1 (sl) 2013-07-31
IL180195A0 (en) 2007-06-03
JP2008503581A (ja) 2008-02-07
US7671015B2 (en) 2010-03-02
US20060229243A1 (en) 2006-10-12
BRPI0512392B1 (pt) 2022-12-13
JP4971150B2 (ja) 2012-07-11
AU2005265266A1 (en) 2006-01-26
PL1768691T3 (pl) 2013-09-30
PT1768691E (pt) 2013-06-20
SG153848A1 (en) 2009-07-29
CA2571542C (en) 2014-08-19
DK1768691T3 (da) 2013-07-01
NZ552274A (en) 2010-06-25
EP1768691A2 (en) 2007-04-04
CN1997383B (zh) 2011-01-05
ES2422173T3 (es) 2013-09-09
WO2006010004A2 (en) 2006-01-26
IL180195A (en) 2014-03-31
EP2545934B1 (en) 2014-12-10
WO2006010004A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
CR9428A (es) Metodos para el tratamiento y la prevencion de fibrosis
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1116169T1 (el) Συνθεσεις και μεθοδοι χρησης πεπτιδιων προνησιδιων και αναλογων εξ' αυτων
CY1116779T1 (el) Αμιδο ενωσεις και η χρηση τους ως φαρμακευτικες ουσιες
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1112487T1 (el) Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη
DE602004005897D1 (de) Verpackte orthodontische anordnung mit klebenden vorbeschichteten geräten
ECSP067062A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
SE0301650D0 (sv) Novel compounds
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
CY1114497T1 (el) ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5
CY1111007T1 (el) Νεος συνδυασμος ενος αναστολεα του φλεβοκομβικου ρευματος if και ενος αναστολεα ασβεστιου και φαρμακευτικες συνθεσεις που τον περιεχουν